Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Anaemia

The safety and efficacy of peginesatide in patients with CKD

Nature Reviews Nephrology volume 9, pages 192–193 (2013)Cite this article

Subjects

Recently published data from four phase 3 safety and efficacy trials show that the synthetic peptide-based, erythropoietin mimetic, peginesatide, is noninferior to conventional erythropoiesis-stimulating agents in increasing haemoglobin levels in patients with chronic kidney disease (CKD). However, peginesatide therapy increased the risk of a combined cardiovascular end point in patients with CKD not on dialysis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wrighton, N. C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458–464 (1996).

    Article  CAS  Google Scholar 

  2. Fishbane, S. et al. Peginesatide in patients with anemia undergoing hemodialysis. N. Engl. J. Med. 368, 307–319 (2013).

    Article  CAS  Google Scholar 

  3. Macdougall, I. C. et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320–332 (2013).

    Article  CAS  Google Scholar 

  4. Stead, R. B. et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietin agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108, 1830–1834 (2006).

    Article  CAS  Google Scholar 

  5. Macdougall, I. C. et al. Does-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 6, 2579–2586 (2011).

    Article  CAS  Google Scholar 

  6. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl. 2, 279–335 (2012).

  7. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).

    Article  CAS  Google Scholar 

  8. Singh, A. K. et al. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).

    Article  CAS  Google Scholar 

  9. Pfeffer, M. A. et al. A trial of darbepoetin α in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  10. Macdougall, I. C. et al. A peptide-based erythropoietin-receptor agonist for pure red cell aplasia. N. Engl. J. Med. 361, 1848–1855 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, University of Erlangen–Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany

    Kai-Uwe Eckardt

Authors
  1. Kai-Uwe Eckardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

K.-U. Eckardt is a consultant for and/or has received speaker's honoraria from Affymax, Amgen, Bayer, GlaxoSmithKline, Johnson & Johnson and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eckardt, KU. The safety and efficacy of peginesatide in patients with CKD. Nat Rev Nephrol 9, 192–193 (2013). https://doi.org/10.1038/nrneph.2013.42

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2013.42

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing